Interpreting the significance of changes in health-related quality-of-life scores.

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175

Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978

Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7)

Barber, M. D., Walters, M. D., & Bump, R. C. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.12.025 · Cited by 1,357

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216

Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Dueck, A. C., Mendoza, T. R., Mitchell, S. A., Reeve, B. B., Castro, K. M., Rogak, L. J., Atkinson, T. M., Bennett, A. V., Denicoff, A. M., O'Mara, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2639 · Cited by 1,030

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial

Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial

Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789

Brivanib versus sorafenib as first‐line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK‐FL study

Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01015 · Cited by 728

Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial

Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657

Impact of Short-Term Preoperative Radiotherapy on Health-Related Quality of Life and Sexual Functioning in Primary Rectal Cancer: Report of a Multicenter Randomized Trial

Marijnen, C. A. M., van de Velde, C. J. H., Putter, H., van den Brink, M., Maas, C. P., Martijn, H., Rutten, H. J., Wiggers, T., Kranenbarg, E. K., Leer, J.-W. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.256 · Cited by 650

Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients

Yost, K. J., Eton, D. T., Garcia, S. F., & Cella, D. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.11.018 · Cited by 597

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30

Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y.-C., & Beer, T. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.025 · Cited by 555

Anxiety Disorders in Cancer Patients: Their Nature, Associations, and Relation to Quality of Life

Stark, D., Kiely, M., Smith, A., Velikova, G., House, A., & Selby, P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.549 · Cited by 496

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33108-2 · Cited by 453

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial

Basch, E., Schrag, D., Henson, S., Jansen, J., Ginos, B., Stover, A. M., Carr, P., Spears, P. A., Jonsson, M., Deal, A. M., et al. (2022) · JAMA · doi:10.1001/jama.2022.9265 · Cited by 413

Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial

Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01998 · Cited by 408

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale

Eton, D. T., Cella, D., Yost, K. J., Yount, S. E., Peterman, A. H., Neuberg, D. S., Sledge, G. W., & Wood, W. C. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.01.012 · Cited by 390

Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences: The FACIT Experience

Yost, K. J., & Eton, D. T. (2005) · Evaluation & the Health Professions · doi:10.1177/0163278705275340 · Cited by 382

Automated Collection of Quality-of-Life Data: A Comparison of Paper and Computer Touch-Screen Questionnaires

Velikova, G., Wright, E. P., Smith, A. B., Cull, A., Gould, A., Forman, D., Perren, T., Stead, M., Brown, J., & Selby, P. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.998 · Cited by 339

An irritable bowel syndrome-specific symptom questionnaire: development and validation

K., W. I., S., F., J., H. C., H., J. R., F., L. G., A., M. E., A., P. R., K., W. I., & J., N. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310004209 · Cited by 324

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270

Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials

Sloan, J., Symonds, T., Vargas-Chanes, D., & Fridley, B. (2003) · Drug Information Journal · doi:10.1177/009286150303700105 · Cited by 242

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Drilon, A., Camidge, D. R., Lin, J. J., Kim, S.-W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2302299 · Cited by 240

Tinnitus Handicap Inventory for Evaluating Treatment Effects: Which Changes Are Clinically Relevant?

Zeman, F., Koller, M., Figueiredo, R., Aazevedo, A., Rates, M., Coelho, C., Kleinjung, T., de Ridder, D., Langguth, B., & Landgrebe, M. (2011) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599811403882 · Cited by 234

Influence of Major Postoperative Complications on Health-Related Quality of Life Among Long-Term Survivors of Esophageal Cancer Surgery

Derogar, M., Orsini, N., Sadr-Azodi, O., & Lagergren, P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3568 · Cited by 217

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): An open-label, randomised, phase 3 trial

Andre, T., Amonkar, M., Norquist, J. M., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D., Garcia-Carbonero, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00064-4 · Cited by 209

Prevalence, severity, and impact of symptoms on female family caregivers of patients at the initiation of radiation therapy for prostate cancer

Fletcher, B. S., Paul, S. M., Dodd, M. J., Schumacher, K., West, C., Cooper, B., Lee, K., Aouizerat, B., Swift, P., Wara, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2838 · Cited by 198

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Mansfield, A. S., Każarnowicz, A., Karaseva, N., Sánchez, A., De Boer, R., Andric, Z., Reck, M., Atagi, S., Lee, J.-S., Garassino, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.021 · Cited by 193

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4209-7 · Cited by 184

A Prospective Study of Quality of Life in Head and Neck Cancer Patients. Part I: At Diagnosis

Hammerlid, E., Bjordal, K., Ahlner‐Elmqvist, M., Boysen, M., Evensen, J. F., Biörklund, A., Jannert, M., Kaasa, S., Sullivan, M., & Westin, T. (2001) · The Laryngoscope · doi:10.1097/00005537-200104000-00021 · Cited by 190

Quality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory Response

Laird, B. J. A., Fallon, M., Hjermstad, M. J., Tuck, S., Kaasa, S., Klepstad, P., & McMillan, D. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7742 · Cited by 162

Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients

Maringwa, J., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., Martinelli, F., Reeve, B. B., Gotay, C., Greimel, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq726 · Cited by 161

Persistence of Restrictions in Quality of Life From the First to the Third Year After Diagnosis in Women With Breast Cancer

Arndt, V., Merx, H., Stegmaier, C., Ziegler, H., & Brenner, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.475 · Cited by 159

Benefit finding and post-traumatic growth in long-term colorectal cancer survivors: prevalence, determinants, and associations with quality of life

Jansen, L., Hoffmeister, M., Chang-Claude, J., Brenner, H., & Arndt, V (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.335 · Cited by 152

Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data

Bordeleau, L., Szalai, J. P., Ennis, M., Leszcz, M., Speca, M., Sela, R., Doll, R., Chochinov, H. M., Navarro, M., Arnold, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.080 · Cited by 148

The clinical significance of quality of life assessments in oncology: a summary for clinicians

Sloan, J. A., Frost, M. H., Berzon, R., Dueck, A., Guyatt, G., Moinpour, C., Sprangers, M., Ferrans, C., Cella, D., & Clinical Significance Consensus Meeting Group (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0085-y · Cited by 149

Association between unmet needs and quality of life of cancer patients: A population-based study

Hansen, D. G., Larsen, P. V., Holm, L. V., Rottmann, N., Bergholdt, S. H., & Søndergaard, J. (2013) · Acta Oncologica · doi:10.3109/0284186x.2012.742204 · Cited by 147

The EORTC QLQ-C30 (version 3.0) quality of life questionnaire: validation study for Spain with head and neck cancer patients

Arraras, J. I., Arias, F., Tejedor, M., Pruja, E., Marcos, M., Martínez, E., & Valerdi, J. (2002) · Psycho-Oncology · doi:10.1002/pon.555 · Cited by 140

Guided Imagery And Progressive Muscle Relaxation as a Cluster of Symptoms Management Intervention in Patients Receiving Chemotherapy: A Randomized Control Trial

Charalambous, A., Giannakopoulou, M., Bozas, E., Marcou, Y., Kitsios, P., & Paikousis, L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156911 · Cited by 135

QOLLTI-F: measuring family carer quality of life.

Cohen, R., Leis, A. M., Kuhl, D., Charbonneau, C., Ritvo, P., & Ashbury, F. D. (2006) · Palliative Medicine · doi:10.1177/0269216306072764 · Cited by 128

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

Jänne, P. A., Ou, S.-H. I., Kim, D.-W., Oxnard, G. R., Martins, R., Kris, M. G., Dunphy, F., Nishio, M., O'Connell, J., Paweletz, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70461-9 · Cited by 127

Feasibility and Compliance of Automated Measurement of Quality of Life in Oncology Practice

Wright, E. P., Selby, P. J., Crawford, M., Gillibrand, A., Johnston, C., Perren, T. J., Rush, R., Smith, A., Velikova, G., Watson, K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.044 · Cited by 119

Young adult cancer survivors' psychosocial well-being: a cross-sectional study assessing quality of life, unmet needs, and health behaviors

Hall, A. E., Boyes, A. W., Bowman, J., Walsh, R. A., James, E. L., & Girgis, A. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-011-1221-x · Cited by 116

Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination

Watt, T., Bjorner, J. B., Groenvold, M., Rasmussen, Å. K., Bonnema, S. J., Hegedüs, L., & Feldt-Rasmussen, U. (2009) · Quality of Life Research · doi:10.1007/s11136-009-9460-8 · Cited by 112

The effect of melatonin on sleep and quality of life in patients with advanced breast cancer

Innominato, P. F., Lim, A. S., Palesh, O., Clemons, M., Trudeau, M., Eisen, A., Wang, C., Kiss, A., Pritchard, K. I., & Bjarnason, G. A. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-015-2883-6 · Cited by 111

One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer

Noal, S., Levy, C., Hardouin, A., Rieux, C., Heutte, N., Ségura, C., Collet, F., Allouache, D., Switsers, O., Delcambre, C., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.037 · Cited by 108

Does pelvic floor muscle training improve female sexual function? A systematic review

Ferreira, C. H. J., Dwyer, P. L., Davidson, M., De Souza, A., Ugarte, J. A., & Frawley, H. C. (2015) · International Urogynecology Journal · doi:10.1007/s00192-015-2749-y · Cited by 106

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.004 · Cited by 102

Effects of meditation on anxiety, depression, fatigue, and quality of life of women undergoing radiation therapy for breast cancer

Kim, Y. H., Kim, H. J., Ahn, S. D., Seo, Y. J., & Kim, S. H. (2013) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2013.06.005 · Cited by 99

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

Harrison, C. N., Mesa, R. A., Kiladjian, J., Al‐Ali, H., Gisslinger, H., Knoops, L., Squier, M., Sirulnik, A., Mendelson, E., Zhou, X., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12375 · Cited by 90

Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer

Marschner, N., Zacharias, S., Lordick, F., Hegewisch-Becker, S., Martens, U., Welt, A., Hagen, V., Gleiber, W., Bohnet, S., Kruggel, L., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.0643 · Cited by 90

All’s Well That Ends Well? Quality of Life and Physical Symptom Clusters in Long-Term Cancer Survivors Across Cancer Types

Zucca, A. C., Boyes, A. W., Linden, W., & Girgis, A. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.04.023 · Cited by 83

Patient Empowerment Improved Perioperative Quality of Care in Cancer Patients Aged ≥ 65 Years – A Randomized Controlled Trial

Schmidt, M., Eckardt, R., Scholtz, K., Neuner, B., von Dossow-Hanfstingl, V., Sehouli, J., Stief, C. G., Wernecke, K.-D., Spies, C. D., & PERATECS Group (2015) · PLOS ONE · doi:10.1371/journal.pone.0137824 · Cited by 87

Distribution and determinants of patient satisfaction in oncology with a focus on health related quality of life

Lis, C. G., Rodeghier, M., Grutsch, J. F., & Gupta, D. (2009) · BMC Health Services Research · doi:10.1186/1472-6963-9-190 · Cited by 86

Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy

Di Meglio, A., Havas, J., Gbenou, A. S., Martin, E., El-Mouhebb, M., Pistilli, B., Menvielle, G., Dumas, A., Everhard, S., Martin, A.-L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.00277 · Cited by 76

The relationship between insomnia and patient satisfaction with quality of life in cancer

Lis, C. G., Gupta, D., & Grutsch, J. F. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-007-0314-z · Cited by 69

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

Novello, S., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.015 · Cited by 66

Quality of life in patients with cancer during the COVID-19 pandemic—A Danish cross-sectional study (COPICADS)

Jeppesen, S. S., Bentsen, K. K., Jørgensen, T. L., Holm, H. S., Holst-Christensen, L., Tarpgaard, L. S., Dahlrot, R. H., & Eckhoff, L. (2021) · Acta Oncologica · doi:10.1080/0284186x.2020.1830169 · Cited by 61

Exercise training improves quality of life in women with subclinical hypothyroidism: a randomized clinical trial

Werneck, F. Z., Coelho, E. F., Almas, S. P., Garcia, M. M. D. N., Bonfante, H. L. M., Lima, J. R. P. D., Vigário, P. D. S., Mainenti, M. R. M., Teixeira, P. D. F. D. S., & Vaisman, M. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000073 · Cited by 57

The cancer patient’s perspective of COVID-19-induced distress—A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic

Koinig, K. A., Arnold, C., Lehmann, J., Giesinger, J., Köck, S., Willenbacher, W., Weger, R., Holzner, B., Ganswindt, U., Wolf, D., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3950 · Cited by 34

Psychological distress and health-related quality of life up to 2 years after oesophageal cancer surgery: nationwide population-based study

Liu, Y. J., Schandl, A., Markar, S., Johar, A., & Lagergren, P. (2021) · BJS Open · doi:10.1093/bjsopen/zraa038 · Cited by 32

Feasibility and impact of a dedicated multidisciplinary rehabilitation program on health-related quality of life in advanced head and neck cancer patients

Passchier, E., Stuiver, M. M., van der Molen, L., Kerkhof, S. I. C., van den Brekel, M. W. M., & Hilgers, F. J. M. (2016) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-015-3648-z · Cited by 28

Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery

Chander, S., Choo, R., Danjoux, C., Morton, G., Pearse, A., Deboer, G., Szumacher, E., Loblaw, A., Cheung, P., & Woo, T. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.11.008 · Cited by 18

Methods for explaining the clinical significance of health status measures

Guyatt, G., Osoba, D., Wu, A., Wyrwich, K., & Norman, G. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85088-3 · Cited by 10